A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
- PMID: 27892728
- DOI: 10.1080/07357907.2016.1213275
A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
Abstract
Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m2 with 20 mg/m2 cisplatin and 250 mg/m2 cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.
Keywords: Abraxane; cisplatin; erbitux; head and neck cancer; radiation therapy.
Similar articles
-
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).Ann Oncol. 2014 Mar;25(3):689-694. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3. Ann Oncol. 2014. PMID: 24496920 Free PMC article. Clinical Trial.
-
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.Cancer. 2013 Feb 15;119(4):766-73. doi: 10.1002/cncr.27741. Epub 2012 Sep 18. Cancer. 2013. PMID: 22991252 Free PMC article. Clinical Trial.
-
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.Med Oncol. 2019 Oct 8;36(11):93. doi: 10.1007/s12032-019-1318-5. Med Oncol. 2019. PMID: 31595355
-
Taxanes as radiosensitizers for head and neck cancer.Curr Opin Oncol. 1999 May;11(3):183-6. doi: 10.1097/00001622-199905000-00008. Curr Opin Oncol. 1999. PMID: 10328592 Review.
-
[Postoperative radiotherapy with cetuximab for head and neck squamous cell carcinoma patients at high risk of recurrence not eligible for cisplatin: A single-center experience and literature review].Cancer Radiother. 2023 Feb;27(1):17-22. doi: 10.1016/j.canrad.2022.04.008. Epub 2022 Jul 16. Cancer Radiother. 2023. PMID: 35853823 Review. French.
Cited by
-
Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas.Pharmaceutics. 2023 Jun 28;15(7):1844. doi: 10.3390/pharmaceutics15071844. Pharmaceutics. 2023. PMID: 37514031 Free PMC article. Review.
-
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.Biomolecules. 2022 Jun 4;12(6):784. doi: 10.3390/biom12060784. Biomolecules. 2022. PMID: 35740909 Free PMC article. Review.
-
Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.Int J Biol Sci. 2020 Jul 19;16(14):2506-2517. doi: 10.7150/ijbs.47068. eCollection 2020. Int J Biol Sci. 2020. PMID: 32792853 Free PMC article. Review.
-
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceut Med. 2019 Aug;33(4):269-289. doi: 10.1007/s40290-019-00288-x. Pharmaceut Med. 2019. PMID: 31933185 Review.
-
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019. Front Oncol. 2019. PMID: 31165040 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
